NCT01953679View on ClinicalTrials.gov

Efficacy Study of Two Continuous Regimens of Oral Daily 5 mg or 10 mg of Ulipristal Acetate (UPA), Versus a Dose of 5.0mg UPA for 24/4 Days

PHASE2CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

August 31, 2015

Study Completion Date

November 30, 2015

Conditions
Focus: Estrogen-free Oral Contraception
Interventions
DRUG

Ulipristal Acetate

Trial Locations (10)

10016

NYU School of Medicine, New York

10032

Columbia University Medical Center, New York

19104

University of Pennsylvania Medical Center, Philadelphia

23507

Eastern Virgina Medical School, Norfolk

45267

University of Cincinnati-Holmes Hospital, Cincinnati

60637

University of Chicago, Chicago

80045

University of Colorado - Denver Anschutz Medical Campus, Aurora

90010

California Family Health Council, Los Angeles

94110

University of California, San Francisco, San Francisco

97239

Oregon Health and Sciences University, Portland

Sponsors

Lead Sponsor

Premier Research
All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Premier Research

OTHER

NCT01953679 - Efficacy Study of Two Continuous Regimens of Oral Daily 5 mg or 10 mg of Ulipristal Acetate (UPA), Versus a Dose of 5.0mg UPA for 24/4 Days | Biotech Hunter | Biotech Hunter